Pyruvate carboxylase deficiency (PCD) is caused by biallelic mutations of the PC gene.
homotetramer localized to the mitochondrial matrix and converts pyruvate into oxaloacetate. PC structures resolved by means of X-ray crystallography suggest that the protein undergoes large conformational transitions over the course of its two-step enzymatic reaction (St Maurice et al., 2007; Xiang & Tong, 2008) . In the first step, a biotin moiety covalently bound to the BCCP domain is carboxylated.
This step requires adenosine triphosphate (ATP), whereas binds to the BC domain and is allosterically activated by acetyl-CoA. In the second step, biotin transfers a carboxyl group to pyruvate. This reaction takes place at the CT domain. The active sites of the BC and CT domains are separated by more than 70 Å in the PC structures of Staphylococcus aureus and Rhibozium etli. Biotin translocation requires large scale molecular motion of the BCCP domain between the BC and CT domains.
Mitochondrial oxaloacetate participates in several critical biochemical pathways. It is converted into aspartate, required for protein synthesis, for the production of argininosuccinate, a metabolite of urea cycle, and for the conversion of glutamate into the neurotransmitter γ-aminobutyric acid (GABA). Oxaloacetate is a component of the tricarboxylic acid (TCA; Kreb's) cycle, and its absence leads to a reduction of mitochondrial nicotinamide adenine dinucleotide, a substrate of complex I of the respiratory chain. During fasting, oxaloacetate is converted into phosphoenolpyruvate, required for gluconeogenesis. Finally, oxaloacetate is necessary for the transport of mitochondrial acetyl-CoA into the cytoplasm, where it participates in the synthesis of fatty acids. Taken together, lack of oxaloacetate due to PCD has a plethora of severe metabolic consequences (Marin-Valencia, Roe, & Pascual, 2010) .
Two clinical subtypes with early onset and fatal outcomes have been defined: A (also called "American type") and B (also called "French type"). Type A PCD manifests several months after birth and presents with increasing generalized developmental delay and hypotonia, failure to thrive, profound apathy, and intermittent lactic acidemia with intercurrent illnesses or other physiologic stress (e.g., infections). All reported patients have died during infancy or early childhood. Few patients with this infantile and always fatal PCD form were reported in the literature (Ahmad et al., 1999; Monnot et al., 2009; Robinson et al., 1987; Wang et al., 2008) .
Type B PCD presents in the first hours after birth with severe lactic acidosis, hyperammonia, hypercitrullinemia, and hypoglycemia.
Immediately following birth, neurological status and consciousness level are typically normal, but after 1-72 hr a hypokinetic-rigid syndrome with profound axial hypotonia appears, which is accompanied by a tremor of the limbs and bizarre ocular movements in some patients. During the first months of life, increasing liver insufficiency and seizures develop in some patients. Patients die within 5 months after birth (Carbone, Applegarth, & Robinson, 2002; Carbone et al., 1998) . Only 38 inactivating mutations in the PC gene have been described in patients with type A and B PCD (Breen et al., 2014; Carbone et al., 1998 Carbone et al., , 2002 Monnot et al., 2009; Ortez et al., 2013; Wang et al., 2008; Wexler et al., 1998) . Several other PCD patients have been reported based on biochemical stigmata of PCD and/or on reduction of pyruvate carboxylase activity, but without molecular confirmation of the diagnosis (Ahmad et al., 1999; Arnold, Griebel, Porterfield, & Brewster, 2001; Brun et al., 1999; Hamilton, Rae, Logan, & Robinson, 1997; Oizumi et al., 1983; Pineda et al., 1995; Robinson et al., 1987; Van Coster, Fernhoff, & De Vivo, 1991; Van Coster, Janssens, Misson, Verloes, & Leroy, 1998) .
Therapeutic options for type A and B disease are limited.
Anaplerotic diet or compounds (e.g., triheptanoin, citrate, or aspartate) have shown variable success in reducing metabolic derangements, but have not achieved an amelioration of the neurological symptoms and a prolongation of life span (Breen et al., 2014; García-Cazorla et al., 2006; Mochel et al., 2005) .
The third form of PCD (type C or benign) is characterized by short episodes of ketoacidosis during infancy and childhood, typically associated with intercurrent illnesses, mild psychological delay and neurologic symptoms, and survival until late adolescence in the six reported patients (Arnold et al., 2001; Hamilton et al., 1997; Higgins, Glasgow, Lusk, & Kerr, 1994; Higgins, Ide, Oghalai, & Polymeropoulos, 1997; Schiff et al., 2006; Van Coster et al., 1991; Wang et al., 2008) . PCD mutations were reported in only two cases (Wang et al., 2008) . Enzymatic activity was reported as 1-10% (of healthy control) in skin fibroblasts or peripheral blood leukocytes in three patients (Arnold et al., 2001; Hamilton et al., 1997; Van Coster et al., 1991) , below 1% in two patients (Schiff et al., 2006; Wang et al., 2008) and was unreported in one patient (Wang et al., 2008) . Thus, the residual enzymatic activity does not appear to be a reliable prognostic parameter in this condition.
Reported genotype/phenotype correlations in both fatal PCD forms (infantile type A and neonatal type B) have been inconsistent.
Initially, it appeared that the presence of at least one truncating mutation in the PC gene led to type B presentation, while biallelic missense mutations lead to type A (Carbone et al., 1998 (Carbone et al., , 2002 Monnot et al., 2009 ). However, additional reports have not been as clear, with type B presentation seen in patients with biallelic missense mutations (Breen et al., 2014; Ostergard et al., 2012; Wang et al., 2008) . Moreover, Wang et al. (2008) hypothesized that mosaicism for mutations in CNS tissues correlated with patient survival.
The genetic difference between type A and C PCD has not been elucidated. Although biallelic mutations in PC have been reported in both, there has not been a clear correlation of genotype with phenotype. The prognosis among type A and type C patients is generally different, dying the former within the first years of life and surviving the latter sometimes until adulthood.
In the current study, we analyzed clinical, electrophysiological, neuroradiological, biochemical, and genetic findings in six patients with PCD, three with type A (patients 1, 2, and 3) and three with type C (patients 4, 5, and 6) PCD. The patients harbor five novel and one known pathogenic variant in PC. We compared the genetic features of these six novel patients with the previously reported type A and type C patients. We created homology models for the full structure of human PC representing two main conformations of the enzyme, where either the BCCP domain is in the vicinity of BC domain or the BCCP domain is adjacent to the CT domain, and we mapped most of COCI ET AL.
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the reported mutations associated with type A and type C PCD onto the models. Together with interpolation of motion between the two structural states of the enzyme, the mapped mutations provided structural insights into the potential effects on the enzyme's function.
Taken together, this study aims to shed further light into the still unclear genotype-phenotype correlation for type A and type C PCD and to provide future PCD patients with a clearer prognosis basing on the revealed genetic mutations.
| PATIENTS AND METHODS

| Patients
Six patients were recruited worldwide from treating metabolic medicine physicians and were included in the study according to clinical and biochemical signs of type A or type C PCD.
| Magnetic resonance imaging (MRI) scan
For patients 1, 3, and 4, brain MRI was performed on a 3-T MR scanner using a standard clinical protocol. For patient 2, brain imaging with spectrography was performed on a 1.5-T MR scanner using a standard clinical protocol. 
| Gene sequencing
| PC enzymatic activity
In patients 2, 3, and 4, the enzymatic activity of pyruvate carboxylase activity was measured in cultured skin fibroblasts from patients 2, 3, and 4 according to standard protocols (Atkin, Utter, & Weinberg 1979; Robinson et al., 1985) . In patients 1, 5, and 6, the enzymatic activity in skin fibroblasts could not be measured due to either technical issues or lack of parental consent.
| Pyruvate carboxylase modeling and variant mapping
Two major conformers of the PC enzyme were modeled to mimic the functional states of biotin carboxylation (conformer 1, PDB ID 2qfc;
St Maurice et al., 2007) and carboxyl transfer to pyruvate (conformer 2, PDB ID 3bg3 and 3bg5; Xiang & Tong, 2008) . In the conformer 1, BCCP domain is adjacent to the BC domain; in the conformer 2, BCCP domain is adjacent to the CT domain. All the homology modeling was performed using Modeller 9.15 (Sali & Blundell, 1993 
| Free energy calculations and PC stability
The changes in PC stability upon each mutation were estimated by the established Rosetta protocol (Kellogg, Leaver-Fay, & Baker, 2011 ) using the Cartesian version of the method (Alford et al., 2017) . Two Rosetta energy functions were used for calculations (Talaris2014 and ref2015; Alford et al., 2017) He had severe lactic acidosis (serum lactate 18.1 mmol/L) and hyperglycemia (136 mg/dl). Ammonia was 53 μmol/l (normal range, 30-60). Organic acids analysis in urine identified elevated lactate and ketones. Initially, a defect in pyruvate dehydroxygenase complex was suspected. The patient was treated with intravenous bicarbonate and he was put on a high-fat diet (50-69%). Acidosis improved but was never completely corrected, with elevated serum lactate (7.6 mmol/L) and base excess (−4.3 mmol/L). At 7 months of age, acute metabolic acidosis occurred with respiratory syncytial virus (RSV) bronchiolitis (serum lactate 9.7 mmol/L). Currently, the patient is 11 months old with the weight of 8,280 g (10th percentile), length 71 cm (third percentile), and head circumference 45 cm (third percentile). His developmental milestones correspond to 5-months of age and he is slightly dystonic.
Brain MRI performed at 6 months showed an increased signal in the putamen, globus pallidus, and caudate bilaterally (Figure 1 ).
Patient 2 (female) is the first child of nonconsanguineous
Aboriginal Canadian parents. At birth, she suffered from lactic acidosis and generalized hypotonia. Birth weight and length were within the normal range, while head circumference was 39 cm (3 cm above 97th percentile). Until the fifth year of age, she was admitted four times due to acute metabolic acidosis and dehydration during minor intercurrent illness. Metabolic studies revealed continuously elevated levels of serum lactate (5-7.5 mmol/L and maximal peak 15 mmol/L during an infection), serum pyruvate (maximal peak 0.28 mmol/L), and alanine (750-1500 µmol/L). Base excess and pH were within the normal range between illnesses and decreased during infection-associated metabolic misbalances, the lowest measured base excess was −13 and the lowest pH was 7.13. At 2 days of age, brain MRI revealed ventriculomegaly with large subependymal cysts and pronounced serum lactate peaks in spectroscopy. Currently, she is 11.5 years old, has a weight of 45.9 kg (75th percentile), length of 147.5 cm (50th percentile), and head circumference of steroids were added for 30 days due to breakthrough infantile spasms. At 6 months of age, he suffered two episodes of metabolic acidosis within a few weeks without an apparent trigger. He was somnolent and hypotonic, had increased serum lactate (10.8 mmol/L), decreased bicarbonate (11 mmol/L) and pH (7.35), normal ammonia and glucose levels and was discharged after intravenous fluid therapy. Plasma alanine, taurine, glutamic acid, glutamine, and proline were almost constantly elevated, while aspartic acid, threonine, citrulline, cystine, lysine, and histidine were intermittently elevated. In the unique cerebrospinal fluid test, alanine and citrulline were elevated. MRI investigation at 2 months of age revealed cystic change in the periventricular white matter, delayed myelination, and underopercularization of the sylvian fissures (Figure 1 ). At the current age of 22 months, the patient fixes objects but does not actively follow them, brings the hands to midline, takes objects with both hands and cannot sit without support. Weight and head circumference are on the 50th percentile and length is on the 75th percentile. He is currently treated with oral Biotin (10 mg daily).
Patient 4 (male) is the first child of nonconsanguineous parents.
Fetal MRI revealed ventriculomegaly with septations and agenesis of the corpus callosum (Figure 1 ). Birth at the 40th pregnancy week and neonatal period were uncomplicated, apart from hyperbilirubinemia.
At 11 months, he suffered from an acute ear infection, and then abruptly developed mental status changes, ultimately becoming comatose, and Kussmaul breathing. Having a pH 6.7 and bicarbonate 2 mmol/L, the patient was resuscitated with intravenous bicarbonate infusion. After this first metabolic crisis, he had permanently elevated levels of urinary ketone bodies and plasma pyruvate and lactate.
Serial biochemical tests revealed constantly increased levels of plasma alanine and intermittently elevated levels of plasma proline and lysine. At 3, 4, and 5 years of age, the patient suffered from acute metabolic acidosis episodes in the setting of cough, RSV infection, and gastroenteritis, respectively. At the current age of 6 years, he has stereotyped movements (hand flapping), walks, jumps, climbs stairs, throws, and catches. He expresses about 10 purposeless sounds but not intelligible words, follows commands and seems to understand speech, plays, and shares with other children, distinguishes strangers from known people. Weight and length are on the 90th percentile.
The patient is currently treated with biotin (10 mg daily), carnitine (50 mg/kg daily), and riboflavin (50 mg daily).
Patient 5 (male) is the second child of nonconsanguineous parents, born to nonconsanguineous parents. He was born at fullterm with normal weight and length. Head circumference was at the 99th percentile. Family's clinical history was unremarkable. At 2 years of age, the child had good motor skills though he walked on his toes, but spoke only a few words. He was given a diagnosis of autism spectrum disorder because of poor eye contact and obsessive behaviour. He subsequently presented at that age to the emergency department with increased work of breathing and significant retractions with afebrile illness and upper respiratory infection. The metabolic evaluation revealed pH 7.07, bicarbonate 6 mmol/L, serum lactate 8.27 mmol/L, and ammonia 45 µmol/L, which normalized with therapy. After paediatric intensive care with intravenous bicarbonate and fluid therapy, pH stabilized to normal. Retrospectively, a smell of ketosis on his breath was reported. He subsequently has had two additional episodes of metabolic acidosis with increased serum lactate (13 and 16 mmol/L) corrected with intensive fluid therapy. (Table 1) .
| Structural modeling of human PC and variant mapping
The constructed homology models represent two conformers of the 
| Predicted PC protein stability
To estimate how the single variant changes the PC stability and whether the protein stability degree is related to the disease phenotype, for each variant we have calculated the total double free energy difference (ΔΔG), double free energy difference of conformer 1 (ΔΔG conformer1 ), double free energy difference of conformer 2 (ΔΔG conformer2 ), and the difference between the latter two ones (ΔΔΔG) as a relative stability indicator between the two conformers ( Table 2 ). The calculations were performed using two energy functions yielding a range of stability estimates which in turn provide an indication for prediction accuracy. shows a potential difference among the two conformers (ΔΔΔG 0.0-6.6 kcal/mol), which may occur due to the stabilization of conformer 2 (BCCP domain interacting with the CT domain; Table 2 ). The variant destabilizes the interaction between BCCP and BC domains (conformer 1), which could perturb the balance between the enzyme conformations.
p.R156Q in the BC domain has a destabilizing effect on the protein, as well as altering the balance between the conformers. In the computational study, we could not estimate the effect of G150 duplication on PC stability, since modeling amino acid duplication would require to perform downstream sequence shifting.
The residue G150 is located in the BC domain adjacent to the ATP binding site.
| Variants in type C patients
Variant p.S266Y destabilizes the protein (ΔΔG of 3.4), while it was not possible to obtain a reliable prediction of the effect of p.S266A on the enzyme's stability. Neither of the variants affects the balance between the conformers in the heterozygotic state (ΔΔΔG 0 kcal/mol and ΔΔΔG −2.2−0.2 kcal/mol, respectively). S266 residue is located in the BC domain. However, the serine side-chain is facing away from the ATP and biotin binding sites: therefore, the contribution of both mutations is mainly due to the altered interactions with the neighboring residues in the BC domain (Figures 3 and S1 ).
Residue p.T569 is located in the CT domain and is not in direct contact to any ligand important for the PC function. The mutation p.T569A is destabilizing (ΔΔG 3.3-3.4 kcal/mol) and does not affect the balance between conformer 1 and conformer 2 (ΔΔΔG 0.0 kcal/mol).
Similarly, variant p.N1081S has a small destabilizing effect on the protein (ΔΔG 3.3-3.4 kcal/mol). N1081 is located in the PT domain and is in direct contact with the interface residues of another PC monomer (Figures 3 and S1 ), therefore it may play a role in the PC tetramerization. Interestingly, in one of the modeled states N1081 is placed closely to the R62 residue of another monomer ( Figure S1) and, as discussed in the previous section, p.R62C variant has an effect on inducing type A PCD. p.N1081S variant may also have an effect on the acetyl-CoA binding: depending on the state considered, the distance between N1081 and the partial structure of ethyl-CoA is smaller than 0.5 nm.
Taken together, three out of four amino acid exchanges harbored by all reported type C patients have an overall small destabilizing effect to the enzyme (for one case, the effect on stability could not be reliably determined) and do not affect the balance between the major PC conformers. The amino acid exchanges present in type A patients manifest in a broad spectrum of the protein stability changes. The type A mutations in most cases appear to substantially disrupt the balance between the major conformational states of the enzyme, indicating a potentially detrimental effect of the genetic variant.
| DISCUSSION
Pyruvate carboxylase deficiency is a rare neurometabolic disease with poor correlation of genotype to phenotype, leading to difficulty Note. ΔΔG values denote changes in the PC stability calculated by thermodynamic modeling of each variant. ΔΔG conformer1 and ΔΔG conformer2 correspond to the changes in stability for the two modeled conformers. ΔΔΔG is the difference between the stability changes between the two conformers for each single variant, and represents the change in balance between the two major conformers in comparison to the WT enzyme. The free energy differences are reported as a range between the values estimated with two energy functions.
in predicting prognosis for patients. A previous study suggested that variants in the 1/3 C-terminal end of the protein could be tolerated and were unlikely to lead to disease since pathogenic missense mutations had been identified only in the 2/3 N-terminal end of the protein (Monnot et al., 2009 (Wang et al., 2008) . We identified an N1081S variant in two patients with type C disease. Since all PCD reports from the pregenome era (Oizumi et al., 1983; Pineda et al., 1995) as well as several others from the genome era (Brun et al., 1999; García-Cazorla et al., 2006; Van Coster et al., 1998) did not describe the pathogenic mutations underlining the phenotypes, any robust hypothesis about genotype-phenotype correlation was difficult.
Some genotype-phenotype correlations seem to be valid. The mutation c.1828 G>A (p.A610T) appears to lead to type A disease, and all 13 Indo-American patients from the Canadian Cree and
Ojibway tribes with this variant had infantile onset of symptoms and death within the first 5 years of life (Carbone & Robinson, 2003; Carbone et al., 1998) . We reported a further Canadian patient with this mutation and type A phenotype.
p.A R631Q mutation has twice been described in patients with type A disease (Monnot et al., 2009; Wang et al., 2009 ). However, since this variant was in compound heterozygosity with p.R270W in one patient and with p.R62C and p.A847V in another patient, a definitive conclusion about of the p.R631Q variant remain speculative. Apart from the p.A610T variant in Canadian First Nation people, no other founder variants have been described in other populations.
As stated above, only six patients with the milder late-onset type C PCD were reported before our study and the PCD causing variants were described in only two of them (Arnold et al., 2001; Hamilton et al., 1997; Schiff et al., 2006; Van Coster et al., 1991; Wang et al., 2008) . Thus, our three type C patients significantly increase our ability to examine mutations in these mild patients. Patient 4 was found to have a heterozygous mutation of serine 266 (p.S266Y), a residue previously reported to be altered in a type C patient (p.S266A; Wang et al., 2009 ). In our patient serine is substituted by tyrosine (p.S266Y) and in the previously reported patient serine was substituted by alanine (p.S266A), two very different amino acids.
Serine 266 is the only amino acid, whose exchange has been reported more than once in association with type C disease. The difference between the two variant amino acids together with the mild phenotype in both patients suggests that the exchange of this residue only mildly alters PC function and causes a mild phenotype.
This hypothesis is supported by the fact that the second variant allele in the previously reported type C patient leads to a stop-codon (p.S705X), thus leading to only one allele in this patient capable of making an abortive protein (Wang et al., 2009 Another interesting scenario that could provide insight into the difference between the type A and type C phenotypes, would be an identification of the p.R631Q mutation in a heterozygous state not coupled with any additional mutations. Looking at the calculated free energy differences, p.R631Q appears to be only mildly destabilizing and to not perturb the balance between the major PC conformers.
This observation would suggest its classification as a type C variant.
However, coupling of this mutation to p.A847V or p.R270W results in a strong PC destabilization or in a disturbed balance between the conformers and finally in a type A phenotype (Monnot et al., 2009; Wang et al., 2008) .
Independently from the associated phenotype, the mutated amino acids from patients 2, 3, 4, 5, and 6 are highly conserved throughout the evolution ( Figure S2 ).
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Several reports have concluded that there is no correlation between residual enzymatic activity in fibroblasts and patient phenotype (Stern, Nayar, Depalma, & Rifai, 1995) . We were only able to measure fibroblast pyruvate carboxylase activity in patients 2 and 3 (type A phenotype) and 4 (type C phenotype), and also found activity higher in the former rather than the latter. Thus, caution is needed when discussing prognosis in newly diagnosed patients with PCD regardless of of enzymatic results. It means that PC activity measurement in skin fibroblast can prove if an unknown variant impairs PC activity, but not to which extent. Of note, all of our patients had germline mutations, and thus tissue mosaicism is unlikely to be playing a role in defining phenotype as has previously been suggested (Wang et al., 2008) .
In the last years, in silico free energy calculations have been increasingly used to estimate the effects of single amino acid mutations on protein stability and protein-ligand binding affinity (Fowler et al., 2018; Gapsys, Michielssens, Seeliger, & de Groot, 2016; Hauser et al., 2018) . According to the results of our structural analysis, the close proximity of the residues G150, R451, A610, According to our in silico models, variants associated with the type C PCD do not directly interact with ATP, biotin, and pyruvate.
Some of these variants (p.S266A, p.S266Y, and p.T569A) are located in the core of the BC and CT domains and destabilize the enzyme.
S266 is neighboring C265 which has been speculated to be important for the CO 2 fixation from the bicarbonate (Li & Cronan, 1992) . This observation matches a positive response of the patient with the p.S266A variant to bicarbonate treatment (Van Coster et al., 1991) .
p.N1081S may have an effect on the interaction between the four PC monomers with each other or might affect the enzyme's activation by acetyl-CoA.
For most of the described variants associated to both type A and type C PCD, free energy calculations predicted a destabilizing effect of the corresponding mutant amino acid on the monomer. Interestingly, for most of the missense variants associated to type A disease the balance between the two major conformational states (conformers 1 and 2) of the enzyme is disturbed; on the contrary, for all type C missense variants the balance between the two conformers appears to be unperturbed. Taken together, we hypothesize that a missense variant, which does not cause a precocious messenger RNA decay, leads to a mutant monomer with a residual enzymatic function and to the consequent mild type C phenotype if this mutant amino acid does not disturb the balance between the two major enzyme conformers. On the contrary, if the mutant amino acid leads to a misbalance between the two main conformers, the global enzymatic function of the mutant homotetramer is impaired to cause a severe type A phenotype.
| CONCLUSION
This study improves our understanding of genotype-phenotype correlation in PCD. Considering the genetic data of all reported patients with type A and C phenotypes, we could observe that a lateonset mild PCD (type C) is not associated to homozygous variants but to heterozygous ones in PC. In general, our in silico calculations of the PC-free energy changes show that mutations which do not destabilize the balance between the two major enzyme conformers are likely to lead to the type C phenotype, while those mutations which affect balance between the two major conformers (regardless of of predicted residual enzymatic activity) lead to a type A phenotype. Identification and characterization of additional PCD patients will help to further refine these predictions.
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